• AAPL 182.74
  • TSLA 174.72
  • AMZN 188
  • MSFT 410.54
  • INTC 30
  • EURUSD 1.0752
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. ST /
  3. ACTI.ST

Active Biotech AB (ACTI ST) stock market data APIs

kr0.818 0.29(54.7%) as of May 8, 2024

Active Biotech AB Financial Data Overview

0.7
0.818
-
0.277
0.372
0.4005-1.478
191 M
362 M
6 225 K
0.35
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ACTI',
Type: 'Common Stock',
Name: 'Active Biotech AB',
Exchange: 'ST',
CurrencyCode: 'SEK',
CurrencyName: 'Swedish krone',
CurrencySymbol: 'kr',
CountryName: 'Sweden',
CountryISO: 'SE',
OpenFigi: NULL,
ISIN: 'SE0001137985',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Active Biotech AB Fundamental Data is available in our Financial Data APIs

  • Net Revenue 6 225 K
  • EBITDA -44 784 000
  • Earnings Per Share -0.17
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Active Biotech AB Earnings via APIs

  • Latest Release 2024-05-08
  • EPS/Forecast NaN

Get Active Biotech AB End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Active Biotech AB latest news via APIs

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab...
  • ACTIVE BIOTECH
  • EUROPEAN REGULATORY NEWS
  • REGULATORY INFORMATION
  • STOCKHOLM STOCK EXCHANGE:ACTI

Annual General Meeting of Active Biotech AB

The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical att...
  • ACTIVE BIOTECH
  • ANNUAL MEETINGS & SHAREHOLDER RIGHTS
  • EUROPEAN REGULATORY NEWS
  • STOCKHOLM STOCK EXCHANGE:ACTI
Do you have any questions?
support@eodhistoricaldata.com